BioSpace News Archive

On behalf of the Honourable Ginette Petitpas Taylor, Minister of Health, Member of Parliament, Matt DeCourcey will announce, in collaboration with the Province of New Brunswick, a new project under the New Brunswick Healthy Seniors Pilot Project.

The Honourable Ginette Petitpas Taylor, Federal Minister of Health, will announce Government of Canada funding towards programs that support mental health within Black Canadian communities.

Today, the Alliance for Aging Research (the “Alliance”) announced the results of a Medicare claims study which found that families and state Medicaid programs, not Medicare, are burdened with the majority of costs associated with Alzheimer’s disease (“Alzheimer’s”, or AD)

Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for Puldysa® (idebenone) in the treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) who are not using glucocorticoids.

The Medicines Company announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of $33.00 per share.

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has completed the rights offering period and will be extending the subscription period until 5:00 PM Eastern time on July 12, 2019,

Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable viral vector drug products, today announced the successful completion of their collaboration to develop synergistic and world leading capabilities.

Over 90% of the public comments sent to FDA in response to its request for public comments on patient preferences in medical devices address FDA’s failed policy on dental amalgam, the 19th -century filling material which is 50% mercury.